Title :

An international survey on the management of patients receiving car t-cell therapy for haematological malignancies on behalf of the chronic malignancies working party of ebmt

Author(s) :

Hayden, P. J. [Auteur]
Sirait, T. [Auteur]
Koster, Linda [Auteur]
Snowden, John A. [Auteur]
Yakoub-Agha, Ibrahim [Auteur]
Lille Inflammation Research International Center - U 995 [LIRIC]

Journal title :

Current Research in Translational Medicine

Abbreviated title :

Curr Res Transl Med

Volume number :

67

Pages :

79-88

Publication date :

2019-08

ISSN :

2452-3186

English keyword(s) :

Patient eligibility
Long-term follow-up
CAR T
CAR T-cells
Patient selection

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Two chimeric antigen receptor (CAR) T-cell therapies - Tisagenlecleucel (Kymriah™™ An online survey with a dual focus on (1) 'real world' patient eligibility criteria and (2) models of care for patient follow-up was sent ...
Show more >Two chimeric antigen receptor (CAR) T-cell therapies - Tisagenlecleucel (Kymriah™™ An online survey with a dual focus on (1) 'real world' patient eligibility criteria and (2) models of care for patient follow-up was sent to experienced physicians. There were 41 respondents (10 countries) and 93% worked in FACT-JACIE-accredited transplant centres. Most felt that a history of malignancy (57%), prior allo-HCT for B-NHL (78%-81%) and prior treatment with anti-CD19/CD3 BiTE antibodies (76%-86%) do not constitute contra-indications to CAR T therapy. Clinicians were divided as to whether CNS involvement represented an exclusion criterion. There was agreement that patients with viral infections (HIV, Hepatitis B or Hepatitis C) are not eligible. There is no common model of care for long-term follow-up. Most respondents believed that patients should attend the hospital two (43%) to three (33%) times weekly during the first month following discharge. A majority (69%) of respondents work in centres where there is an MDT meeting with a specific focus on follow-up following CAR T Therapy. Follow-up care is currently delivered either in HCT or haematology-oncology outpatient clinics. The responses reveal wide variation in perceived patient eligibility criteria and highlight the need for consensus guidelines. The findings also illustrate the embryonic nature of current follow-up arrangements.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-30T10:27:45Z
2024-03-22T14:38:06Z